
Conference Coverage
Latest News

Enzyme Replacement in Pancreatic Cancer: What Pharmacists Should Know

A Pharmacist's Checklist for Coordinating Care

Male Mice Develop More Severe Zika Neurological Disease Despite Comparable Viral Loads

Cemdisiran Approved as First siRNA Therapy for Myasthenia Gravis

FDA Approves Venglustat, First Treatment for Neurological Symptoms of GD3

Shorts










Continuing Education
All News

In the phase 3 REGAL trial, galinpepimut-S reached a median overall survival of 24.0 months, compared with 14.7 months for best available treatment, in patients in second or later remission.

Technology empowers patients and optimizes medication use.

Health-system pharmacists confirm therapy matches stroke mechanism, screen for bleeding risk and drug interactions, and help patients transition to outpatient care.

Balanced exposure to clinical and nonclinical careers, timed to each pathway's application calendar and built into each curriculum's structure, can help pharmacy students choose their next step deliberately.

Peer Reviewed
Identifying and screening Medicare Part D patients who are ordered brand-name cardiovascular medications for PACE/PACENET eligibility before discharge can reduce patients’ out-of-pocket costs for these medications.

Neladalkib received accelerated approval for adults with advanced ALK-positive NSCLC after specified prior therapies, supported by durable responses in the ALKOVE-1 trial.

Adrabetadex cut the risk of death by 55%, but its boxed warning for permanent hearing loss means patients need regular hearing tests.

A once-nightly drop already used to reverse pupil dilation gains a near-vision indication.

PAHO confirmed endemic measles transmission in the US, Mexico, and Bolivia, putting pharmacists' role in vaccination and case detection in focus.

Safe storage and responsible disposal help protect patients from accidental poisoning and drug misuse while keeping medications stable and effective.

A new US DOL rule will require PBMs to disclose their compensation to large self-insured employer plans starting in 2027.

Salia Farrokh, PharmD, MBA, describes how neurocritical care pharmacists have moved from answering questions to leading research, policy, and teaching, and why health systems must fund dedicated ICU pharmacists and protected time to sustain that growth.

FDA Approves Secukinumab as First IL-17 Biologic for Polymyalgia Rheumatica
The FDA approved secukinumab for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate tapering, supported by improved sustained remission and reduced steroid exposure in REPLENISH.

Preserving patient access requires attention to the people, workflows, and financial structures behind the pharmacy counter, not just the number of open pharmacy locations.

The breakthrough is not only in cell and gene therapies but also in whether health care can translate them into practice.

A clear and workable medication plan is an essential part of the transition home.

The FDA's decision comes weeks ahead of giredestrant's scheduled approval date.

Adults with AChR antibody–positive generalized myasthenia gravis now have a C5 inhibitor they can inject themselves at home once a week.

Semaglutide-Associated Sensory Skin Disturbance in Patients Without Diabetes Treated for Weight Loss
Peer Reviewed
This case series describes 2 instances of cutaneous sensory disturbance during semaglutide therapy in patients without diabetes and discusses possible mechanisms as hypotheses requiring further investigation.

Vorasidenib analyses featured at SNO 2026 examine longer-term outcomes and seizure burden in IDH-mutant glioma, underscoring the importance of sustained monitoring during oral therapy.

Dexmedetomidine is approved, becoming the first at-home treatment for schizophrenia-associated agitation.

The pertuzumab biosimilar is set to be commercially available in the third quarter of 2028.

Pharmacists can help identify uncontrolled risk factors, review medications, and reinforce when patients should seek emergency care.



































